Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21912594 | 0.78 | AURKA (0.34) | — | |
| SCHEMBL4254350 | 0.77 | EP300 (0.34) | — | |
| SCHEMBL28293858 | 0.77 | — | — | |
| SCHEMBL24871115 | 0.76 | — | — | |
| SCHEMBL1225898 | 0.75 | ALB (0.38) | — | |
| SCHEMBL13586939 | 0.75 | — | — | |
| SCHEMBL16869991 | 0.75 | AURKA (0.33) | — | |
| SCHEMBL2194330 | 0.75 | — | — | |
| SCHEMBL13351590 | 0.75 | HASPIN (0.30) | — | |
| SCHEMBL26275912 | 0.75 | TET2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114150041-B | Reagents and methods for analysis of associated nucleic acids | CS遗传学有限公司 | 2025-06-17 | — | — | CN | claimed |
| WO-2025061911-A1 | METHODS OF PRODUCING NUCLEOTIDE TRIPHOSPHATES (NTPS) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-27 | — | — | WO | claimed |
| EP-4368726-A2 | REAGENTS AND METHODS FOR THE ANALYSIS OF LINKED NUCLEIC ACIDS | CS Genetics Limited (GB) | 2024-05-15 | — | — | EP | claimed |
| WO-2023183841-A2 | COMPOSITIONS AND METHODS FOR TET-ASSISTED OXIDATION OF METHYLATED NUCLEOTIDE BASES | EXACT SCIENCES CORPORATION (US) | 2023-09-28 | — | — | WO | claimed |
| EP-3587589-B1 | REAGENTS AND METHODS FOR THE ANALYSIS OF CIRCULATING MICROPARTICLES | CS GENETICS LTD (GB) | 2023-09-13 | — | — | EP | claimed |
| EP-4103740-A1 | NANOPORE DEVICE AND METHODS OF DETECTING AND CLASSIFYING CHARGED PARTICLES USING SAME | Palogen, Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| CN-114150041-A | Reagents and methods for analyzing associated nucleic acids | CS遗传学有限公司 | 2022-03-08 | — | — | CN | claimed |
| WO-2021163163-A1 | NANOPORE DEVICE AND METHODS OF DETECTING AND CLASSIFYING CHARGED PARTICLES USING SAME | PALOGEN, INC. (US) | 2021-08-19 | — | — | WO | claimed |
| US-20210254136-A1 | Methods for the Analysis of Circulating Microparticles | CS GENETICS LIMITED (GB) | 2021-08-19 | — | — | US | claimed |
| US-20210247378-A1 | NANOPORE DEVICE AND METHODS OF DETECTING AND CLASSIFYING CHARGED PARTICLES USING SAME | PALOGEN INC (US) | 2021-08-12 | — | — | US | claimed |
| EP-3814526-A1 | METHODS FOR THE ANALYSIS OF CIRCULATING MICROPARTICLES | CS Genetics Limited (GB) | 2021-05-05 | — | — | EP | claimed |
| US-20170253924-A1 | METHOD FOR GENOMIC PROFILING OF DNA 5-METHYLCYTOSINE AND 5-HYDROXYMETHYLCYTOSINE | SHANGHAI EPICAN GENETECH CO. LTD | 2017-09-07 | — | — | US | claimed |
| WO-2012078637-A2 | COMPOSITION AND METHOD FOR OLIGONUCLEOTIDE DELIVERY | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| EP-0284549-B1 | MAGNETIC FLUID COMPOSITIONS | Silica Gel Ges.mbH Absorptionstechnik, Apparatebau (DE) | 1992-07-15 | — | — | EP | claimed |
| EP-4713459-A2 | ANTI-VISTA ANTIBODY RNA OR NUCLEIC ACID CONJUGATES (ARCS OR ANCS), COMPOSITIONS CONTAINING, AND THERAPEUTIC USE THEREOF | LIFORDI IMMUNOTHERAPEUTICS, INC. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12527665-B2 | Methods for identifying modified bases in nucleic acid templates | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4622651-A1 | INHIBITORY NUCLEIC ACIDS AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-0285057-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| US-4728730-A | Synthesis of nucleoside thiophosphoanhydrides | WISCONSIN ALUMINI RESEARCH FOUNDATION (US) | 1988-03-01 | — | — | US | disclosed |
| EP-0151001-A2 | Nonradiometric polynucleotide probes | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527665-B2 | Methods for identifying modified bases in nucleic acid templates | POLM, POLL, PNP | APP 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.